RECORD | Already taken place We, 20.3.2024
In this webinar, you’ll discover how SPR can be multiplexed and automated to enable high-throughput, data-rich drug candidate screening against multiple target proteins.Go to the webinar
Information-Rich Drug Discovery Enabled by Next-Generation Multiplexing SPR
Technology Networks: Information-Rich Drug Discovery Enabled by Next-Generation Multiplexing SPR
Detailed validation is key in successful drug development. Surface plasmon resonance (SPR) offers a label-free, direct-binding analysis that brings additional insights into drug kinetics compared to established functional assays.
SPR gives detailed information on affinity, complex half-life, thermodynamic constants and mode-of-action of potential candidates.
In this webinar, you’ll discover how SPR can be multiplexed and automated to enable high-throughput, data-rich drug candidate screening against multiple target proteins.
Attend this webinar to discover:
- The relevance of kinetics and SPR for your drug development project
- The value of multiplexing assays for drug development
- Bruker’s newest Triceratops SPR #64, its flexibility and throughput in drug discovery and development pipelines
Presenter: Dr. Cyrill George Brunner (Senior Application Specialist, Bruker Daltonics)
